GlassScriptPhysician profile
Prasad D Gupta
NPI 1659686970
$2,936.19
in general payments reported to CMS, 2019-2025
23 companies · $652 in 2025
The $652 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $168 · 2021: $441 · 2022: $511 · 2023: $309 · 2024: $376 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $822.47 | 2019-2025 | Lifevest |
| Abiomed | $354.03 | 2021-2025 | Impella |
| Janssen Pharmaceuticals, INC | $280.02 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $204.17 | 2019-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $183.17 | 2019-2025 | Navitor, Gallant |
| Edwards Lifesciences Corporation | $151.04 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $148.72 | 2019-2024 | |
| Philips North America LLC | $141.88 | 2020-2022 | |
| Pfizer INC. | $97.65 | 2019-2024 | |
| Amgen INC. | $93.18 | 2022-2023 | Repatha |
| Medtronic, INC. | $89.84 | 2024-2025 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $76.02 | 2021-2024 | Verquvo |
| Daiichi Sankyo INC. | $50.17 | 2023-2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $45.00 | 2019-2023 | Eliquis |
| Medtronic Vascular, INC. | $31.38 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2021-2022 | |
| Novo Nordisk INC | $22.28 | 2023 | Rybelsus, Ozempic |
| Shockwave Medical, INC | $21.53 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $20.89 | 2022 | |
| Amarin Pharma, INC. | $19.31 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.07 | 2023 | Arcalyst |
| Infobionic, INC | $14.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.